Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966

doi:10.1016/J.TET.2013.08.037

Paper

DOI: 10.1016/J.TET.2013.08.037

Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966

Published Oct 28, 2013 · Guo‐Liang Lu, Amir Ashoorzadeh, R. Anderson

Tetrahedron

Q3 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

This study demonstrates an efficient two-step synthesis of 5-(bromomethyl)-1-methyl-4-nitro-1 H-imidazole, a key precursor for the preparation of hypoxia-selective pan-ErbB inhibitor SN29966, and its analogues.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1158/1535-7163.TARG-11-A247

Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.

SN29966 shows single-agent antitumor activity in mice bearing A431 and SKOV3 xenografts, with potential for clinical trials in early 2012.

2011·5citations·J. Smaill et al.·Molecular Cancer Therapeutics

Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.TARG-09-B76

Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor

SN29966, a hypoxia-activated pan-HER inhibitor, shows promising antitumor activity in preclinical models, with potential for broad therapeutic index in cancer treatment.

2009·8citations·A. Patterson et al.·Molecular Cancer Therapeutics

Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.TARG-09-C46

Abstract C46: Design and identification of the novel hypoxia‐activated irreversible pan‐HER inhibitor SN29966

SN29966, a hypoxia-activated pan-HER inhibitor, shows promising anti-proliferative activity against A431 cells in lung cancer, potentially broadening its therapeutic index and reducing toxicity.

2009·3citations·J. Smaill et al.·Molecular Cancer Therapeutics

Molecular Cancer Therapeutics

DOI: 10.1021/JM030308B

Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.

Pharmacokinetic optimization is needed for gene-directed enzyme prodrug therapy, as current prodrugs show limited activity against NTR+ve cells in tumors.

2003·62citations·M. Hay et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1021/JM021030A

Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.

Megazol shows more activity against protozoan parasites than its derivatives, and shows potential as an effective treatment for sleeping sickness and Chagas disease in primates.

2003·123citations·G. Chauvière et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1002/1521-4184(200203)335:2/3<69::AID-ARDP69>3.0.CO;2-8

Synthesis and Antihypertensive Activities of New 1, 4‐Dihydropyridine Containing Nitroimidazolyl Substituent with a Nitrooxy Group at the 3‐Ester Position

New 1,4-dihydropyridine analogues with a nitrooxy group at the 3'-ester position show antihypertensive activity similar to nifedipine and TNG.

2002·14citations·A. Shafiee et al.·Archiv der Pharmazie

Archiv der Pharmazie

DOI: 10.1021/JM0005555

6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

These 6-substituted-4-(3-bromophenylamino)quinazoline derivatives show potential as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced anti

2001·236citations·H. Tsou et al.·Journal of medicinal chemistry

Journal of medicinal chemistry

DOI: 10.1002/CHIN.200032029

Palladium‐Catalyzed Cyanation Reactions of Aryl Chlorides.

Palladium-catalyzed cyanation effectively enables the cyanation of both electron-deficient and electron-rich aryl chlorides, making it the first successful method.

2000·101citations·F. Jin et al.·ChemInform

ChemInform

DOI: 10.1021/JP972311A

Pulse Radiolysis Studies on the Fragmentation of Arylmethyl Quaternary Nitrogen Mustards by One-Electron Reduction in Aqueous Solution

Pulse radiolysis studies reveal that benzyl-type radicals can be produced from the radical anions of 4-nitro-5-imidazole and 5-nitro-2-pyrrole derivatives, but not from those of 2-nitrobenzene and 4-nitrobenzene.

1997·54citations·R. Anderson et al.·Journal of Physical Chemistry A

Journal of Physical Chemistry A

Citations

DOI: 10.3390/cells10051006

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

Modulating tumor hypoxia may improve cancer immunotherapy responsiveness by addressing resistance mechanisms in checkpoint inhibitors.

2021·66citations·Z. Fu et al.·Cells

Cells

DOI: 10.1002/asia.201801826

Hypoxia-Activated Prodrugs of PERK Inhibitors.

Hypoxia-activated prodrugs of PERK inhibitors show potential for tumor-selective drug delivery, targeting tumor growth and resistance without causing normal tissue toxicity.

2019·9citations·L. Liew et al.·Chemistry, an Asian journal

Chemistry, an Asian journal

DOI: 10.1039/c8ra08023b

First synthesis of novel 2,4-bis((E)-styryl)quinoline-3-carboxylate derivatives and their antitumor activity

Novel 2,4-bis((E)-styryl)quinoline-3-carboxylate derivatives show significant antitumor activity, with IC50 values significantly lower than cisplatin.

2018·4citations·W. Gao et al.·RSC Advances

RSC Advances